Site icon pharmaceutical daily

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Outlook 2019-2023 with Bayer, Gilead Sciences, Novartis, TG Therapeutics, and Verastem Leading the Competition – ResearchAndMarkets.com

BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

Recent approvals

Although many approved therapies are available for various types of blood cancer, the market still witnesses a huge unmet need. Chemotherapies are widely used for the treatment of several types of cancer, including lymphomas. However, chemotherapies have some limitations, which reduces patient adherence toward the treatment.

Such factors have fuelled exhaustive research on target therapies such as PI3K inhibitors for the treatment of cancer. Several drugs have been approved, such as copanlisib (ALIQOPA) for the treatment of FL, in September 2017. Thus, recent approvals are expected to fuel the PI3K inhibitors market to grow at a CAGR of about 5% during the forecast period.

Reimbursement programs

The cost of PI3K inhibitors is usually high, owing to the complex manufacturing process. This has also had a negative impact on the PI3K inhibitors market for a long time. Therefore, various government bodies have started patient assistance programs to reduce the cost burden on patients and make these treatments available at an affordable price. Thus, the availability of reimbursement programs is expected to fuel the growth of the PI3K inhibitors market size during the forecast period.

Market Dynamics

The report also looks at factors such as recent approvals, strategic alliances, and special drug designations. However, low adoption of drugs, clinical trial failures, and stringent regulations may hamper the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

Segment Coverage

The phosphoinositide 3-kinase inhibitors market analysis considers sales from chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL), and other indications. This analysis also considers the sales of phosphoinositide 3-kinase inhibitors in Asia, Europe, North America, and RoW.

In 2018, the CLL segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high prevalence of CLL and FL and increasing new cases of cancer will play a significant role in the CLL segment to maintain its market position.

Competitive Landscape

With the presence of few major players, the global phosphoinositide 3-kinase inhibitors market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphoinositide 3-kinase inhibitors manufacturers, that include:

Also, the phosphoinositide 3-kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY APPLICATION

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For more information about this report visit https://www.researchandmarkets.com/r/i4kgfs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Enzymes

Exit mobile version